Furthermore, in BRAF-mutant melanoma cells, the increased activity of the MAPK pathway results in the inhibition of the genetic programme regulated by TFEB, leading to tumour progression and chemoresistance to BRAF inhibitors [33]. This evidence concerns the gene BRAF and neoplasm.